Literature DB >> 25662098

Syndecan-1 regulates the biological activities of interleukin-34.

Aude I Segaliny1, Regis Brion2, Erwan Mortier3, Mike Maillasson3, Michel Cherel4, Yannick Jacques3, Benoît Le Goff2, Dominique Heymann5.   

Abstract

IL-34 is a challenging cytokine sharing functional similarities with M-CSF through M-CSFR activation. It also plays a singular role that has recently been explained in the brain, through a binding to the receptor protein tyrosine phosphatase RPTPβ/ζ. The aim of this paper was to look for alternative binding of IL-34 on other cell types. Myeloid cells (HL-60, U-937, THP-1) were used as cells intrinsically expressing M-CSFR, and M-CSFR was expressed in TF-1 and HEK293 cells. IL-34 binding was studied by Scatchard and binding inhibition assays, using 125I-radiolabelled cytokines, and surface plasmon resonance. M-CSFR activation was analysed by Western blot after glycosaminoglycans abrasion, syndecan-1 overexpression or repression and addition of a blocking anti-syndecan antibody. M-CSF and IL-34 induced different patterns of M-CSFR phosphorylations, suggesting the existence of alternative binding for IL-34. Binding experiments and chondroitinase treatment confirmed low affinity binding to chondroitin sulphate chains on cells lacking both M-CSFR and RPTPβ/ζ. Amongst the proteoglycans with chondroitin sulphate chains, syndecan-1 was able to modulate the IL-34-induced M-CSFR signalling pathways. Interestingly, IL-34 induced the migration of syndecan-1 expressing cells. Indeed, IL-34 significantly increased the migration of THP-1 and M2a macrophages that was inhibited by addition of a blocking anti-syndecan-1 antibody. This paper provides evidence of alternative binding of IL-34 to chondroitin sulphates and syndecan-1 at the cell surface that modulates M-CSFR activation. In addition, IL-34-induced myeloid cell migration is a syndecan-1 dependent mechanism.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-receptor chondroitin sulphate; Cytokine bioavailability; Interleukin-34; M-CSFR; M2a macrophage; Syndecan-1

Mesh:

Substances:

Year:  2015        PMID: 25662098     DOI: 10.1016/j.bbamcr.2015.01.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  Interleukin 34 (IL-34) cell-surface localization regulated by the molecular chaperone 78-kDa glucose-regulated protein facilitates the differentiation of monocytic cells.

Authors:  Sayaka Ogawa; Yukiko Matsuoka; Miho Takada; Kazue Matsui; Fumihiro Yamane; Eri Kubota; Shiori Yasuhara; Kentaro Hieda; Naoki Kanayama; Naoya Hatano; Hiroshi Tokumitsu; Masaki Magari
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

Review 2.  Functions of interleukin-34 and its emerging association with rheumatoid arthritis.

Authors:  Ren-Peng Zhou; Xiao-Shan Wu; Ya-Ya Xie; Bei-Bei Dai; Wei Hu; Jin-Fang Ge; Fei-Hu Chen
Journal:  Immunology       Date:  2016-09-23       Impact factor: 7.397

Review 3.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Authors:  Noah Sorrelle; Adrian T A Dominguez; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

Review 4.  Immunoregulatory properties of the cytokine IL-34.

Authors:  Carole Guillonneau; Séverine Bézie; Ignacio Anegon
Journal:  Cell Mol Life Sci       Date:  2017-03-03       Impact factor: 9.261

Review 5.  Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor.

Authors:  Violeta Chitu; E Richard Stanley
Journal:  Curr Top Dev Biol       Date:  2016-12-01       Impact factor: 4.897

6.  IL-34 and protein-tyrosine phosphatase receptor type-zeta-dependent mechanisms limit arthritis in mice.

Authors:  Hilda Minerva González-Sánchez; Jea-Hyun Baek; Julia Weinmann-Menke; Amrendra Kumar Ajay; Julia Forgan-Farnam Charles; Masaharu Noda; Ruth Anne Franklin; Patricia Rodríguez-Morales; Vicki Rubin Kelley
Journal:  Lab Invest       Date:  2022-03-14       Impact factor: 5.502

Review 7.  Emerging proteoglycans and proteoglycan-targeted therapies in rheumatoid arthritis.

Authors:  Brianna Hurysz; Nunzio Bottini
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-27       Impact factor: 5.282

8.  Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma.

Authors:  Zhendong Wang; Jun Zhu; Tianyi Wang; Hao Zhou; Jinjie Wang; Zhanghao Huang; Haijian Zhang; Jiahai Shi
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

9.  Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor.

Authors:  Katrien Van Raemdonck; Sadiq Umar; Karol Palasiewicz; Michael V Volin; Hatem A Elshabrawy; Bianca Romay; Chandana Tetali; Azam Ahmed; M Asif Amin; Ryan K Zomorrodi; Nadera Sweiss; Shiva Shahrara
Journal:  Arthritis Rheumatol       Date:  2021-09-22       Impact factor: 10.995

10.  Receptor-Type Protein-Tyrosine Phosphatase ζ and Colony Stimulating Factor-1 Receptor in the Intestine: Cellular Expression and Cytokine- and Chemokine Responses by Interleukin-34 and Colony Stimulating Factor-1.

Authors:  Stephanie Zwicker; Daniela Bureik; Madeleen Bosma; Gisele Lago Martinez; Sven Almer; Elisabeth A Boström
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.